FIERCEBIOTECH

Bayer is pulling the plug on its $670 million CAR-T pact with Atara Biotherapeutics. Three months after a death paused a study of the lead...

Despite mRNA powerhouses Pfizer and Moderna continuing to tower over the COVID-19 vaccine market, there still are plenty of biotechs hoping to...

Vertex is doubling down on cell and genetic therapy R&D. Having recently opened a 400-person center in Boston, the biotech has set out plans for...

Satellite Bio has told mission control it’s ready for launch, blasting out of stealth mode with $110M in seed and series A funding to rocket its...

Kaleido Therapeutics has faced the music. The microbiome-focused biotech is packing up shop after a dismal eight months of setbacks punctuated...

All Takeda is trying to do with its billions-of-dollars worth of licensing deals in gene therapy is cure rare disease. Simple, right? Madhu...

BioMarin’s commercial aspirations for its hemophilia gene therapy remain on ice after the FDA lobbed additional questions for the company to...

For decades, the FDA has been offering accelerated approvals to open early access to new cancer drugs, but mostly for patients who’ve already...

Intellia Therapeutics' CRISPR-powered T cell therapy, which uses the gene editing method to reprogram a sample of the patient's immune cells,...

Although rare diseases are individually rare, around the globe nearly 400 million people suffer from approximately 7,000 different rare...